STAT

Nerd’s notes: How we did the ClinicalTrials.gov data analysis

I have a dream that one day all public information and all software will be free, transparent, and open source, and all people will have the skills to benefit from it. We are not living in my dream world yet. But here at STAT, we’re trying to do our part to open up a little more data stored in government databases.

Our first major project after we launched was a deep data-intensive dive into clinical trials compliance. In December 2015, we published “Failure to Report,” an investigation of the reporting of human study results to ClinicalTrials.gov by government, academic, and industry scientists. We found flagrant violations of federal law and non-existent enforcement.

We didn’t just publish and hope for the best. We went back this year to check whether research organizations were doing a better job posting results. That appears to.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Approval For Sarepta Drug, MSF Closing Access Campaign And More
After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a controversial, long-running saga:
STAT2 min read
STAT+: Pharmalittle: We’re Reading About EMA Plans For GLP-1 Shortages, Walgreens Store Closings, And More
The European Medicines Agency and member countries announced several steps to address shortages of GLP-1 drugs.

Related Books & Audiobooks